Skip to main content
. 2023 Jun 14;28(10):894–900. doi: 10.1093/oncolo/oyad132

Table 3.

Most common (>5% incidence) treatment-related adverse events.

TRAE, n (%) All grade Grade 1 Grade 2 Grade 3
Hypertension 21 (46) 10 (22) 9 (20) 2 (4)
Dysphonia 7 (15) 7 (15)
Asthenia 6 (13) 2 (4) 3 (7) 1 (2)
Diarrhea 5 (11) 4 (9) 1 (2)
Fatigue 4 (9) 3 (7) 1 (2)
Rash 3 (7) 1 (2) 2 (4)

No grade 5 TRAEs occurred during this study. Two grade 4 TRAEs (duodenal ulcer hemorrhage, hyperbilirubinemia) occurred once in a single patient.

Abbreviation: TRAE, treatment-related adverse event.